Professor Michael Barry:

To expand, we meet every week and review all of the drugs. In the assessment process in Europe various agencies often examine and compare them. We find a positive decision can be made in one country and a negative in another, and if we think about it this should not surprise us. We have EUnetHTA, the European Union network of health technology assessment. I do not see harmonisation of assessments in Europe from a health technology assessment point of view and not from pricing happening any time soon, and I will tell the committee why.